Home Stock Ideas Long Ideas Healthcare  Summary Pro-Dex reported nice Q1 sales of $19.9 million, which is up 14.6% YoY. Their largest customer contract now runs through December 2028, reducing potential near-term risks in that sense. Also, their APM acquisition gives them more control over their supply chain and brings some potential aerospace/defense optionality. PDEX’s Monogram CVRs could still be meaningful over the long run, which is another positive worth considering. Overall, PDEX’s higher valuation and customer concentration are my main caveats. Yet, they’re still a “buy” in the long-term view. Monty Rakusen/DigitalVision via Getty Images Pro-Dex, Inc. ( PDEX ) is a specialized medical instrument manufacturer that develops surgical handpieces. These items are often useful for orthopedic, thoracic, and craniomaxillofacial procedures.…